D-0105-2021 Class III Terminated

Recalled by Fresenius Kabi USA, LLC — Lake Zurich, IL

FDA drug recall D-0105-2021 was initiated by Fresenius Kabi USA, LLC on Nov 17, 2020 and is designated Class III. Reason for recall: Cross Contamination with Other Products: trace amounts of octreotide found during testing The recall status is terminated (terminated Aug 25, 2022). Affected quantity: 16,986 vials.

Recall details

Product Type
Drugs
Report Date
Dec 2, 2020
Initiation Date
Nov 17, 2020
Termination Date
Aug 25, 2022
Voluntary/Mandated
Voluntary: Firm initiated
Product Quantity
16,986 vials

Product description

DOXOrubicin Hydrochloride Injection, USP, 10 mg / 5 mL (2 mg / mL), 5 mL fill in a 6 mL vial, Single Dose Vial, Rx only, Sterile, Fresenius Kabi, Lake Zurich, IL 60047. NDC: 63323-883-05

Reason for recall

Cross Contamination with Other Products: trace amounts of octreotide found during testing

Distribution pattern

Nationwide USA and Puerto Rico

Code information

Batch: 6120525, exp 11/2020

Source

Dataset
openFDA drug recall enforcement reports
FDA record
This recall in openFDA (JSON)
Enforcement Report
Search FDA's Enforcement Report for D-0105-2021
openFDA file date
Nov 10, 2026
Loaded by RegDataLab
Nov 11, 2026

These dates say when openFDA published the data file and when RegDataLab last loaded it.

Source: openFDA record for D-0105-2021. Report a data issue: hello@regdatalab.com.